Title |
Protein kinase Cβ as a therapeutic target stabilizing blood–brain barrier disruption in experimental autoimmune encephalomyelitis
|
---|---|
Published in |
Proceedings of the National Academy of Sciences of the United States of America, August 2013
|
DOI | 10.1073/pnas.1302569110 |
Pubmed ID | |
Authors |
Tobias V. Lanz, Simon Becker, Matthias Osswald, Stefan Bittner, Michael K. Schuhmann, Christiane A. Opitz, Sadanand Gaikwad, Benedikt Wiestler, Ulrike M. Litzenburger, Felix Sahm, Martina Ott, Simeon Iwantscheff, Carl Grabitz, Michel Mittelbronn, Andreas von Deimling, Frank Winkler, Sven G. Meuth, Wolfgang Wick, Michael Platten |
Abstract |
Disruption of the blood-brain barrier (BBB) is a hallmark of acute inflammatory lesions in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis. This disruption may precede and facilitate the infiltration of encephalitogenic T cells. The signaling events that lead to this BBB disruption are incompletely understood but appear to involve dysregulation of tight-junction proteins such as claudins. Pharmacological interventions aiming at stabilizing the BBB in MS might have therapeutic potential. Here, we show that the orally available small molecule LY-317615, a synthetic bisindolylmaleimide and inhibitor of protein kinase Cβ, which is clinically under investigation for the treatment of cancer, suppresses the transmigration of activated T cells through an inflamed endothelial cell barrier, where it leads to the induction of the tight-junction molecules zona occludens-1, claudin 3, and claudin 5 and other pathways critically involved in transendothelial leukocyte migration. Treatment of mice with ongoing experimental autoimmune encephalomyelitis with LY-317615 ameliorates inflammation, demyelination, axonal damage, and clinical symptoms. Although LY-317615 dose-dependently suppresses T-cell proliferation and cytokine production independent of antigen specificity, its therapeutic effect is abrogated in a mouse model requiring pertussis toxin. This abrogation indicates that the anti-inflammatory and clinical efficacy is mainly mediated by stabilization of the BBB, thus suppressing the transmigration of encephalitogenic T cells. Collectively, our data suggest the involvement of endothelial protein kinase Cβ in stabilizing the BBB in autoimmune neuroinflammation and imply a therapeutic potential of BBB-targeting agents such as LY-317615 as therapeutic approaches for MS. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
United States | 1 | 1% |
Unknown | 72 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 15 | 20% |
Researcher | 14 | 19% |
Student > Master | 11 | 15% |
Student > Postgraduate | 8 | 11% |
Student > Bachelor | 6 | 8% |
Other | 12 | 16% |
Unknown | 8 | 11% |
Readers by discipline | Count | As % |
---|---|---|
Neuroscience | 17 | 23% |
Agricultural and Biological Sciences | 17 | 23% |
Medicine and Dentistry | 13 | 18% |
Biochemistry, Genetics and Molecular Biology | 7 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
Other | 7 | 9% |
Unknown | 10 | 14% |